1309 GMT - AstraZeneca's revenue miss in oncology segment should concern investors but its long-term story seems intact, Barclays analysts say in a note. The British pharma giant posted mixed 1Q results as some of its oncology and rare disease drugs fell short of company-compiled sales consensus, the analysts say. "While we believe investors would question the oncology misses, important catalyst readouts planned for later this year and AstraZeneca being less susceptible to the ever​-​emerging tariff situation in the U.S., we see AstraZeneca as best positioned in our coverage," they say. Shares are down 0.3% at 104.90 pounds. (helena.smolak@wsj.com)

(END) Dow Jones Newswires

April 29, 2025 09:09 ET (13:09 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.